Biotech: Page 16
-
Maddie Meyer via Getty Images
Moderna shares tumble on slashed sales guidance
The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV vaccines.
By Delilah Alvarado • Jan. 13, 2025 -
Getty Images
Gene editingTune raises $175M for hepatitis B medicine, epigenetic research
The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat chronic hepatitis B infections.
By Gwendolyn Wu • Jan. 12, 2025 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Getty Images
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets
Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.
By BioPharma Dive staff • Jan. 10, 2025 -
Permission granted by Intellia Therapeutics
Intellia to stop work on rare disease therapy, lay off staff
The CRISPR company will reduce its workforce by 27% over the course of the year as it discontinues a treatment for alpha-1 antitrypsin deficiency.
By Ned Pagliarulo • Jan. 10, 2025 -
Getty Images
Immune resetOuro, backed by GSK, joins hunt to bring bispecifics to autoimmune disease
“Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani.
By Ben Fidler • Jan. 10, 2025 -
Getty Images
Healthcare venture capital investment boosted by AI in 2024: report
Nearly 30% of the funding poured into healthcare startups last year, including for biotechs, went to companies leveraging artificial intelligence, according to Silicon Valley Bank.
By Emily Olsen • Jan. 9, 2025 -
Getty Images
Verdiva starts up with $411M and a portfolio of obesity drugs from China
The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind Biosciences, led by an oral therapy ready for Phase 2 testing.
By Kristin Jensen • Jan. 9, 2025 -
Permission granted by Maze Therapeutics
Kidney disease drugmaker Maze files for IPO
Maze fits the mold of biotechs that have pulled off successful offerings recently: The seven-year old startup, which raised about $500 million privately, has a drug in Phase 2 testing.
By Gwendolyn Wu • Jan. 8, 2025 -
Getty Images
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results
The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative reaction to data for its hives drug and Stoke finalized Phase 3 trial plans.
By BioPharma Dive staff • Jan. 8, 2025 -
Courtesy of Galapagos
Galapagos, after research struggles, will split in two and revamp Gilead deal
Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its current workforce.
By Kristin Jensen • Jan. 8, 2025 -
Courtesy of Vertex Pharmaceuticals
Vertex, startup Orna to partner on gene editing research
The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.
By Delilah Alvarado • Jan. 7, 2025 -
Getty Images
Metsera reveals data supporting long-acting obesity shot
The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug as a future threat to weight loss medicines from Novo Nordisk and Eli Lilly.
By Jonathan Gardner • Jan. 7, 2025 -
Courtesy of Novo Holdings
Orbis raises $93M to turn popular biologics into pills
The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against “validated blockbuster biologic targets.”
By Gwendolyn Wu • Jan. 6, 2025 -
Getty Images
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got long-awaited data and BioNTech settled with the NIH.
By BioPharma Dive staff • Jan. 2, 2025 -
Getty Images
Ionis gets a milestone approval; Another top FDA official to step down
The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest FDA leader to leave the agency, and two biotechs cut research deals.
By BioPharma Dive staff • Dec. 20, 2024 -
Getty Images
A venture firm breathes new life into an old NGM drug
A startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple metabolic disorders, for an unspecified rare condition.
By Gwendolyn Wu • Dec. 19, 2024 -
Courtesy of Vertex Pharmaceuticals
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint
Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ahead in the indication.
By Jacob Bell • Dec. 19, 2024 -
Kyodo/Newscom
Ottimo raises $140M to compete in chase for new type of cancer drug
Led by former Seagen CEO David Epstein, the startup claims it has a drug that could stand out from other PD1- and VEGF-blocking cancer treatments.
By Ben Fidler • Dec. 19, 2024 -
Getty Images
Tessera gets sickle cell funding; Corvus shares slide on eczema data
The Bill & Melinda Gates Foundation will invest up to $50 million in Tessera’s in vivo sickle cell therapy. Elsewhere, Cara agreed to a reverse merger and J&J had a drug application rejected.
By BioPharma Dive staff • Dec. 18, 2024 -
K_E_N via Getty Images
A Vertex partner — and potential rival — secures $100M to develop non-opioid pain drugs
“Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The company plans to use its new funds to get to “proof of concept” for its medicines.
By Jacob Bell • Dec. 18, 2024 -
Jacob Bell/BioPharma Dive
Jazz to search for new chief as CEO plans retirement
Bruce Cozadd, who co-founded the company two decades ago, will step down once a successor is found. Jazz aims to complete its search within one year.
By Ned Pagliarulo • Dec. 16, 2024 -
Spencer Platt via Getty Images
Edgewise weighs fast approval path for muscular dystrophy drug
The biotech company will meet with regulators to discuss Phase 2 biomarker data that sent its shares climbing by more than 20% Monday.
By Ned Pagliarulo • Dec. 16, 2024 -
Getty Images
Novo builds up manufacturing; Pepgen Duchenne trial put on hold
Novo Nordisk is investing more than $1 billion in a new production facility in Denmark. Elsewhere, drugs from Neurocrine Biosciences, Checkpoint and Galderma won new FDA approvals.
By BioPharma Dive staff • Dec. 16, 2024 -
Permission granted by Maat Pharma
Sponsored by MaaT PharmaCould the gut microbiome hold the key to fighting cancer?
MaaT Pharma is at the forefront of innovation in this field, striving to achieve the first-ever approval of a microbiome-driven immunomodulator in oncology.
Dec. 16, 2024 -
Getty Images
CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug
In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that deny coverage of Qalsody because it’s “experimental and investigational.”
By Jacob Bell • Dec. 13, 2024
Previous
